Form 4: Verona Pharma CFO's Equity Converted in Acquisition

Verona Pharma plc's Chief Financial Officer, Mark W. Hahn, reported the disposition of ordinary shares and conversion of equity awards into cash following the company's acquisition by Merck Sharp & Dohme LLC.

Summary

• Mark W. Hahn, Chief Financial Officer of Verona Pharma plc, reported significant changes in his beneficial ownership of the company's securities.
• These transactions occurred on October 7, 2025, as a direct result of a Scheme of Arrangement under which Verona Pharma plc was acquired by Merck Sharp & Dohme LLC and its subsidiary, Vol Holdings LLC.
• Hahn disposed of 11,264,968 Ordinary Shares, which were acquired from him as part of the Scheme of Arrangement.
• He also had 3,285,280 Ordinary Shares, derived from performance-based restricted share unit (PRSU) awards, vest and were immediately disposed of as part of the acquisition.
• All outstanding time-based restricted share unit (RSU) awards and performance-based restricted share unit (PRSU) awards held by Hahn became fully vested immediately prior to the acquisition's effective time.
• These vested RSU and PRSU awards were automatically converted into a cash payment based on the ADS Consideration.
• Each Ordinary Share was valued at $13.375 in cash, and each American Depositary Share (ADS), representing eight Ordinary Shares, was valued at $107 in cash.
• Following these transactions, Mark W. Hahn beneficially owns 0 Ordinary Shares and 0 derivative securities of Verona Pharma plc.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for the reporting person, Mark W. Hahn, as his equity holdings and awards were converted into a substantial cash payout due to the successful acquisition. For shareholders, it represents a positive liquidity event at a fixed price. While the company ceases independent operation, the financial outcome for equity holders is favorable.

Positives

• Shareholders, including the Chief Financial Officer, received a significant cash payout as part of the acquisition, with Ordinary Shares valued at $13.375 each and ADSs at $107 each.
• The acquisition provided a clear exit strategy and liquidity for equity holders.
• All restricted share unit awards (RSUs and PRSUs) held by the CFO became fully vested and were converted into cash, representing a substantial financial gain for the reporting person.

Negatives

• Verona Pharma plc will cease to be an independent publicly traded entity following its acquisition by Merck Sharp & Dohme LLC.
• The company's shares will no longer be available for public trading, impacting investors seeking to hold or trade VRNA stock.

Future Outlook

The filing indicates the completion of Verona Pharma plc's acquisition by Merck Sharp & Dohme LLC, implying the company will no longer operate as an independent entity. The future outlook for the former Verona Pharma business will be as part of Merck's operations.

Industry Context

This announcement reflects a consolidation event within the pharmaceutical industry, where a larger entity, Merck Sharp & Dohme LLC, has acquired a smaller, specialized biopharmaceutical company, Verona Pharma plc. Such acquisitions are common for larger pharmaceutical companies seeking to expand their pipeline or market presence through strategic M&A.

Stakeholder Impact

• Shareholders received a cash payment for their shares, providing liquidity and a return on investment.
• Employees, including the Chief Financial Officer, had their equity awards vested and converted to cash, impacting their personal financial positions.
• The company's independent operations will cease, affecting its employees and potentially its operational structure.

Next Steps

• Verona Pharma plc will be integrated into Merck Sharp & Dohme LLC's operations.
• The company's shares will be delisted from public exchanges.

Key Dates

Keywords

Verona Pharma, VRNA, SEC Form 4, Insider Transaction, Acquisition, Merck Sharp & Dohme, Scheme of Arrangement, Chief Financial Officer, Share Disposition, Equity Awards, Restricted Share Units, Cash Payout